Last reviewed · How we verify
ALE.F02
ALE.F02 is a small molecule targeting the SGLT2 receptor.
ALE.F02 is a small molecule targeting the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | ALE.F02 |
|---|---|
| Sponsor | Alentis Therapeutics AG |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, ALE.F02 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Rescue of Nephrons With ALE.F02 (RENAL-F02) (PHASE2)
- A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALE.F02 CI brief — competitive landscape report
- ALE.F02 updates RSS · CI watch RSS
- Alentis Therapeutics AG portfolio CI